Skip to main content

Loading...

Insights
Newsletter
SMS Pharmaceuticals - Q2FY27 Results Update

Midas Equities and Research

05 November 2026

8 min read

SMS Pharmaceuticals - Q2FY27 Results Update

Download ReportDownload Report

Let’s Spark a
conversation

Whether you're an investor seeking disciplined strategies or a business exploring growth capital, we'd welcome a conversation.

Get in Touch

All fields are required. After submit, a confirmation message appears below the button.

First name

Last name

Email address

Who We Are

About Spark Capital Group
Why Spark Capital?
Careers
Events
Regulatory Information

What We Do

Private Wealth Management

Investment Banking

Investment Management

Whom We Serve

Individual Families
Family Offices
Corporates

Get In Touch

Contact Us
Register A Complaint

Consolidated Investor Charter

Spark Capital Advisors (India) Private Limited (SCA) has gone through a process of reorganisation in 2022 and demerged its institutional equities business (stock broking license and research analyst license) to Spark Institutional Equities Private Limited (SIEPL) through a Composite Scheme of Demerger. Further the shares of SIEPL have been bought by Avendus Capital Private Limited with effect from December 20, 2022. SCA, its affiliates and its related parties, do not have any connection or relation with SIEPL

All Rights reserved. Copyright © 2026.
SPARK CAPITAL ADVISORS (INDIA) PVT LTD

Terms of Use|Privacy Policy|Disclaimer

Spark Capital

Spark Capital
PWM

Spark Investment
Management

Spark Capital

SMS Pharmaceuticals - Q2FY27 Results Update | Insight